Although rituximab and abatacept have been shown to partially reduce the level of ACPA in RA patients in close association with a reduction of disease activity [150,151], Cambridge et al. discovered that there was no increase in the level of ACPA prior to or during relapse following initial response [152]. Here, PRTN3 is linked to rheumatoid arthritis.